Open an account

Immunovant

IMVT · NASDAQ

$28.59+$0.97 (+3.51%)TodayMarket closed ·
Prev close $27.62

About IMVT

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The firm is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Employees
362
Headquarters
New York City, New York
Listed
May 14, 2019
Sector
Health Care
Industry
Biotechnology
Website
immunovant.com

IMVT key statistics

Market cap
5.91B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.66M
Volume
1.45M
Open price
$27.76
High today
$29.14
Low today
$27.62
52 Week high
$45.42
52 Week low
$17.68

Immunovant (IMVT) at a glance

As of Oct 20, 2026, Immunovant (IMVT) shares are priced at $28.59, giving the company a market cap of 5.91B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $27.62 and $29.14. The current price is 3.5% above the day's low and 1.9% below its high.

Volume so far is 1.45M shares, in line with the average of 1.66M shares a day.

Over the past year Immunovant has ranged from $17.68 to $45.42, and now sits 39% of the way up that range.

Immunovant met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.75 per share against an estimate of -$0.6277.

The average analyst price target is $49.78, 74.1% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 8 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 18 analystsAvg $49.78
Low
$30.30
Now
$28.59
High
$69.30

IMVT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 6.5% on average.

  1. Q4 FY24: reported -$0.52 per share against an estimate of -$0.4352
  2. Q1 FY25: reported -$0.60 per share against an estimate of -$0.5379
  3. Q2 FY25: reported -$0.74 per share against an estimate of -$0.609
  4. Q3 FY25: reported -$0.76 per share against an estimate of -$0.7642
  5. Q4 FY25: reported -$0.64 per share against an estimate of -$0.7309
  6. Q1 FY26: reported -$0.73 per share against an estimate of -$0.6129
  7. Q1 FY27: reported -$0.75 per share against an estimate of -$0.6277
  8. Q2 FY26: reported -$0.75 per share against an estimate of -$0.6277

IMVT news

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

  • Press releaseBusiness Wire

    IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law

  • Avi Kapoor

    Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

  • Press releasePRNewswire

    Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

  • Vandana Singh

    Immunovant Ends Autoimmune Skin Disorder Program

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

  • Press releaseGlobe Newswire

    Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

  • Press releaseGlobe Newswire

    Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Similar companies

Companies in the same industry as Immunovant

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.